Wockhardt Pharma (WOCKPHARMA) has reported strong Q1 FY27

!WOCKPHARMA Wockhardt Pharma has reported results with a net profit of ₹107 crore, marking a sharp turnaround from losses last year. The company is focusing on biotech expansion, insulin launches, and has shareholder approval for a ₹3,000 crore capital raise. 📊 Wockhardt Pharma Latest News (September 2026) 🔑 Financial Highlights Revenue (Q1 FY27): ₹929 crore QoQ: Down 3.7% from ₹965 crore YoY: Up 25.9% from ₹738 crore Operating Profit: ₹192 crore YoY growth: 868% Net Profit (PAT): ₹107 crore YoY growth: 199% EBITDA Margin: Expanded to 20.2% EPS: ₹6.55 (vs. ₹10.23 in Mar 2026) 📈 Stock Market Performance NSE Price (22 Sept 2026): ₹2,212 BSE Price (22 Sept 2026): ₹2,217.60 1-Year Gain: +48% Promoter Holding: 49.1% Valuation: P/E ratio at 86.7, reflecting high investor expectations 🚀 Strategic Developments Capital Raise: Shareholder approval for up to ₹3,000 crore via QIP/public offerings. Biotech Focus: Expanding into insulin analogs and novel drugs. Pipeline: Targeting 50% of revenue from novel drugs within 5 years. Key Drug: Antibiotic Zaynich approved by CDSCO, with US launch expected by year-end. Peak Sales Target: $1.5 billion from Zaynich 📰 Industry Context Pharma Rally: Nifty Pharma index up 2% recently, with peers like Laurus Labs and Piramal Pharma also surging. Wockhardt Stock Movement: Up 75% in one month, hitting all-time highs on regulatory approvals. 📌 Key Takeaways for Investors Strong turnaround: From losses to consistent profitability. High growth potential: Driven by biotech and novel drug launches. Risks: Elevated valuation makes the stock sensitive to execution delays in insulin launches or margin pressures. Opportunity: Strategic capital raise and global expansion could fuel long-term growth.